


Appendix 1. Kaplan–Meier analysis of overall survival in patients with stage I–II ovarian cancer according to the expression of CD44variant 6 (CD44v6). There were significant differences in overall survival between the CD44-high and CD44-low groups ($P=.045$). HR, hazard ratio; CI, confidence interval.



No. at risk							
CD44v6-high	30	25	15	10	4	4	0
CD44v6-low	56	50	44	30	18	7	0

Motohara T, Fujimoto K, Tayama S, Narantuya D, Sakaguchi I, Tashiro H, Katabuchi, H. CD44 variant 6 as a predictive biomarker for distant metastasis in patients with epithelial ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 by The American College of Obstetricians and Gynecologists

Page 1 of 1